Oral delivery of Glucagon like peptide-1 by a recombinant Lactococcus lactis

Pharmaceutical Research

Volumn 31, Issue 12, 2014, Pages 3404-3414

  Agarwal, Payal ^a   Khatri, Pulkit ^b   Billack, Blasé ^b   Low, Woon Kai ^b   Shao, Jun ^b  

^a NOTRE DAME OF MARYLAND UNIVERSITY   (United States)

^b ST JOHN'S UNIVERSITY   (United States)

Author keywords

GLP 1; L. lactis; normal flora; oral protein delivery; type 2 diabetes

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCOSE BLOOD LEVEL; INSULIN;

ANIMAL; BIOSYNTHESIS; BLOOD; DIABETES MELLITUS, TYPE 2; DOG; DRUG DELIVERY SYSTEM; DRUG EFFECTS; GENETICS; GLUCOSE BLOOD LEVEL; LACTOCOCCUS LACTIS; MALE; MDCK CELL LINE; MESOCRICETUS; METABOLISM; PANCREAS ISLET BETA CELL; RAT; ZUCKER RAT;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOGS; DRUG DELIVERY SYSTEMS; GLUCAGON-LIKE PEPTIDE 1; INSULIN; INSULIN-SECRETING CELLS; LACTOCOCCUS LACTIS; MADIN DARBY CANINE KIDNEY CELLS; MALE; MESOCRICETUS; RATS; RATS, ZUCKER;

EID: 84936102267     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-014-1430-3     Document Type: Article

References (47)

1. Perfetti R, Brown TA, Velikina R, Busselen S. Control of glucose homeostasis by incretin hormones. Diabetes Technol Ther. 1999;1(3):297-305.
2. Kim W, Egan JM. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev. 2008;60(4):470-512.
3. Vilsboll T. On the role of the incretin hormones GIP and GLP-1 in the pathogenesis of Type 2 diabetes mellitus. Dan Med Bull. 2004;51(4):364-70.
4. Elliott RM, Morgan LM, Tredger JA, Deacon S, Wright J, Marks V. Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns. J Endocrinol. 1993;138(1):159-66.
5. Kjems LL, Holst JJ, Volund A, Madsbad S. The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes. 2003;52(2):380-6.
6. Perry T, Greig NH. The glucagon-like peptides: a double-edged therapeutic sword? Trends Pharmacol Sci. 2003;24(7):377-83.
7. Mest HJ, Mentlein R. Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes. Diabetologia. 2005;48(4):616-20.
8. Mentlein R. Dipeptidyl-peptidase IV, (CD26)-role in the inactivation of regulatory peptides. Regul Pept. 1999;85(1):9-24.
9. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. 2011;141(1):150-6.
10. Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med. 2013;173(7):534-9.
11. [01/10/2014]; Available from: http://www.fda.gov/Drugs/DrugSafety/ucm343187.htm.
12. Bond A. Exenatide (Byetta) as a novel treatment option for type 2 diabetes mellitus. Proc (Bayl Univ Med Cent). 2006;19(3):281-4.
13. Moriya H, Moriwaki C, Akimoto S, Yamaguchi K, Iwadare M. Studies on the passage of alpha-chymotrypsin across the intestine. Chem Pharm Bull (Tokyo). 1967;15(11):1662-8.
14. Shao J, Kaushal G. Normal flora: living vehicles for non-invasive protein drug delivery. Int J Pharm. 2004;286(1-2):117-24.
15. Antolin J, Ciguenza R, Saluena I, Vazquez E, Hernandez J, Espinos D. Liver abscess caused by Lactococcus lactis cremoris: a new pathogen. Scand J Infect Dis. 2004;36(6-7):490-1.
16. Shanahan F. Immunology. Therapeutic manipulation of gut flora. Science. 2000;289(5483):1311-2.
17. Buchelli-Ramirez HL, Alvarez-Alvarez C, Rojo-Alba S, Garcia-Clemente M, Cimadevilla-Suarez R, Pando-Sandoval A, et al. Necrotising pneumonia caused by Lactococcus lactis cremoris. Int J Tuberc Lung Dis. 2013;17(4):565-7.
18. Kaushal G, Trombetta L, Ochs RS, Shao J. Delivery of TEM beta-lactamase by gene-transformed Lactococcus lactis subsp. lactis through cervical cell monolayer. Int J Pharm. 2006;313(1-2):29-35.
19. Piard JC, Hautefort I, Fischetti VA, Ehrlich SD, Fons M, Gruss A. Cell wall anchoring of the Streptococcus pyogenes M6 protein in various lactic acid bacteria. J Bacteriol. 1997;179(9):3068-72.
20. Savijoki K, Kahala M, Palva A. High level heterologous protein production in Lactococcus and Lactobacillus using a new secretion system based on the Lactobacillus brevis S-layer signals. Gene. 1997;186(2):255-62.
21. Le Loir Y, Nouaille S, Commissaire J, Bretigny L, Gruss A, Langella P. Signal peptide and propeptide optimization for heterologous protein secretion in Lactococcus lactis. Appl Environ Microbiol. 2001;67(9):4119-27.
22. Brashears MM, Galyean ML, Loneragan GH, Mann JE, Killinger-Mann K. Prevalence of Escherichia coli O157:H7 and performance by beef feedlot cattle given Lactobacillus direct-fed microbials. J Food Prot. 2003;66(5):748-54.
23. Brashears MM, Jaroni D, Trimble J. Isolation, selection, and characterization of lactic acid bacteria for a competitive exclusion product to reduce shedding of Escherichia coli O157:H7 in cattle. J Food Prot. 2003;66(3):355-63.
24. Tannock GW. Probiotic properties of lactic-acid bacteria: plenty of scope for fundamental R & D. Trends Biotechnol. 1997;15(7):270-4.
25. Gilbert C, Atlan D, Blanc B, Portailer R, Germond JE, Lapierre L, et al. A new cell surface proteinase: sequencing and analysis of the prtB gene from Lactobacillus delbruekii subsp. bulgaricus. J Bacteriol. 1996;178(11):3059-65.
26. Grangette C, Muller-Alouf H, Goudercourt D, Geoffroy MC, Turneer M, Mercenier A. Mucosal immune responses and protection against tetanus toxin after intranasal immunization with recombinant Lactobacillus plantarum. Infect Immun. 2001;69(3):1547-53.
27. Scheppler L, Vogel M, Marti P, Muller L, Miescher SM, Stadler BM. Intranasal immunisation using recombinant Lactobacillus johnsonii as a new strategy to prevent allergic disease. Vaccine. 2005;23(9):1126-34.
28. Scheppler L, Vogel M, Zuercher AW, Zuercher M, Germond JE, Miescher SM, et al. Recombinant Lactobacillus johnsonii as a mucosal vaccine delivery vehicle. Vaccine. 2002;20(23-24):2913-20.
29. Shaw DM, Gaerthe B, Leer RJ, Van Der Stap JG, Smittenaar C, Heijne Den Bak-Glashouwer M, et al. Engineering the microflora to vaccinate the mucosa: serum immunoglobulin G responses and activated draining cervical lymph nodes following mucosal application of tetanus toxin fragment C-expressing lactobacilli. Immunology. 2000;100(4):510-8.
30. Zegers ND, Kluter E, van Der Stap H, van Dura E, van Dalen P, Shaw M, et al. Expression of the protective antigen of Bacillus anthracis by Lactobacillus casei: towards the development of an oral vaccine against anthrax. J Appl Microbiol. 1999;87(2):309-14.
31. Steidler L, Neirynck S, Huyghebaert N, Snoeck V, Vermeire A, Goddeeris B, et al. Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10. Nat Biotechnol. 2003;21(7):785-9.
32. Steidler L, Hans W, Schotte L, Neirynck S, Obermeier F, Falk W, et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science. 2000;289(5483):1352-5.
33. Steidler L, Robinson K, Chamberlain L, Schofield KM, Remaut E, Le Page RW, et al. Mucosal delivery of murine interleukin-2 (IL-2) and IL-6 by recombinant strains of Lactococcus lactis coexpressing antigen and cytokine. Infect Immun. 1998;66(7):3183-9.
34. Steidler L, Wells JM, Raeymaekers A, Vandekerckhove J, Fiers W, Remaut E. Secretion of biologically active murine interleukin-2 by Lactococcus lactis subsp. lactis. Appl Environ Microbiol. 1995;61(4):1627-9.
35. Avall-Jaaskelainen S, Palva A. Secretion of biologically active porcine interleukin-2 by Lactococcus lactis. Vet Microbiol. 2006;115(1-3):278-83.
36. Fernandez A, Horn N, Wegmann U, Nicoletti C, Gasson MJ, Narbad A. Enhanced secretion of biologically active murine interleukin-12 by Lactococcus lactis. Appl Environ Microbiol. 2009;75(3):869-71.
37. Klijn N, Weerkamp AH, de Vos WM. Genetic marking of Lactococcus lactis shows its survival in the human gastrointestinal tract. Appl Environ Microbiol. 1995;61(7):2771-4.
38. Kaushal G, Shao J. Oral delivery of beta-lactamase by Lactococcus lactis subsp. lactis transformed with Plasmid ss80. Int J Pharm. 2006;312(1-2):90-5.
39. Jakubovics NS, Stromberg N, van Dolleweerd CJ, Kelly CG, Jenkinson HF. Differential binding specificities of oral streptococcal antigen I/II family adhesins for human or bacterial ligands. Mol Microbiol. 2005;55(5):1591-605.
40. Wells JM, Wilson PW, Le Page RW. Improved cloning vectors and transformation procedure for Lactococcus lactis. J Appl Bacteriol. 1993;74(6):629-36.
41. Mukherjee T, Squillantea E, Gillespieb M, Shao J. Transepithelial electrical resistance is not a reliable measurement of the Caco-2 monolayer integrity in Transwell. Drug Deliv. 2004;11(1):11-8.
42. Cogburn JN, Donovan MG, Schasteen CS. A model of human small intestinal absorptive cells. 1. Transport barrier. Pharm Res. 1991;8(2):210-6.
43. Wells JM, Mercenier A. Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria. Nat Rev Microbiol. 2008;6(5):349-62.
44. Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, et al. MDCK (Madin-Darby canine kidney) cells: a tool for membrane permeability screening. J Pharm Sci. 1999;88(1):28-33.
45. Prego C, Torres D, Alonso MJ. The potential of chitosan for the oral administration of peptides. Expert Opin Drug Deliv. 2005;2(5):843-54.
46. Kompella UB, Lee VH. Delivery systems for penetration enhancement of peptide and protein drugs: design considerations. Adv Drug Deliv Rev. 2001;46(1-3):211-45.
47. Gomez-Orellana I. Strategies to improve oral drug bioavailability. Expert Opin Drug Deliv. 2005;2(3):419-33.